A Phase 1 interventional study of ADSTEM Inj. (Adult human mesenchymal stem cells) in Atopic Dermatitis, sponsored by EHL Bio Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-12-22.
Sponsored by EHL Bio Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Dermatitis, Atopic with a site in Korea, Republic of — 7 open to participants now, 18 under way, 7 of them phase 3. Dermatitis, Atopic · Korea, Republic of.
Among the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, this one is the 71st largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2016, is one of 4 in phase 1, and was the 16th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →7 of the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
EHL Bio Co., Ltd. · Sites in Korea, Republic of
Ages 19–70
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Argentina and 14 more countries
Ages 18–100
LEO Pharma · Sites in Korea, Republic of, United States, Belgium and 10 more countries
Ages 6 mo–11 yrs
Pfizer · Sites in Korea, Republic of
Ages 12+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 19 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 39 · Phase 4 1
First in 2007; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 234 across the 71 interventional studies, 101 across the 12 observational. Of the 58 that completed or were terminated, 32 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 83 have an industry lead sponsor. The 10 most frequent:
EHL Bio Co., Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
EHL Bio Co., Ltd. has 4 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatitis, Atopic with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06718101AbbVieA Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | 2027-05 |
| NCT07217015Kymera Therapeutics, Inc.A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | 2027-06 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 5 to your calendar (.ics) → With an account.
Among the 83 studies in Dermatitis, Atopic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of autologous mesenchymal stem cells. The study is composed of two steps. Step 1 is to determine clinically proper dose capacity of the ADSTEM Inj. and step 2 is to evaluate exploratory efficacy of the ADSTEM Inj. at the proper dose.
Atopic dermatitis (AD) is a type of inflammation of the skin. It results in itchy, swollen, red, and cracked skin. The symptoms typically start in childhood with changing severity over the years. The pathogenesis of AD is characterized by excessive type 2 helper T cell mediated inflammatory responses, resulting in B lymphocyte mediated increase in serum level of immunoglobulin E (IgE). Subsequent degranulation of mast cells by IgE releases various inflammatory mediators, which recruit the lymphocytes and eosinophils into the lesion.
Current clinical management of AD includes topical corticosteroids and systemic immunosuppressants. However, these drugs have been reported to carry the risk of side-effects and severe.
Several recent studies including ours have demonstrated that mesenchymal stem cells (MSCs) could suppress allergic responses in AD. MSCs have been known to interact with cell types of both innate and adaptive immune systems, which results in the suppressive effect on proliferation, differentiation, and activation of immune cells including T cells, B cells, dendritic cells, and natural killer cells. Indeed, a number of studies have reported that the immunomodulatory ability of MSCs can be usefully applied for the treatment of autoimmune and inflammation-related diseases such as asthma, rhinitis, and dermatitis. Therefore, MSCs has possibility as a new drug for AD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study. 2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.
Drug: ADSTEM Inj. (Adult human mesenchymal stem cells)
Comparison of different dosages of the drug in the aspect of safety and efficacy.
Also known as: ADSTEM Inj.
The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03
physical exam, vital sign, laboratory findings, and adverse drug reactions
Time frame: 12 weeks follow-up after treatment
The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of SCORAD index as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of each index score of SCORAD index as contrasted with baseline value
TBSA, erythema, edema/papulation, oozing/crusting, excoriation, lichenification, dryness, pruritus, and insomnia
Time frame: 12 weeks follow-up after treatment
The variation of the degrees of disease as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of investigator's global assessment (IGA) as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of eczema area and severity index (EASI) total score as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value
Time frame: 12 weeks follow-up after treatment
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2016, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EHL Bio Co., Ltd.